^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

6275 / 13 - DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment

Published date:
03/15/2023
Excerpt:
In Pfeiffer (A677 mutation) and WSU-DLCL2 (Y641 mutation) CDX models, DW91170 showed improved tumor regression activity with no significant abnormal signs such as weight loss.